Scinai Launches CDMO Division to Fund R&D Pipeline
Scinai, an Israeli biotech firm, has shifted to a dual business model that pairs contract development and manufacturing services with its internal drug research. Investors watch closely to see if the new CDMO unit delivers enough revenue to cover the high costs of advancing therapeutic candidates.